Nplate

10.10.2022 • News

HHS Says Nplate Order not Sign of Nuclear Threat

The US Department of Health and Human Services (HHS) said last week it has budgeted $290 million to stock up on Amgen’s Nplate (romiplostim), a drug primarily used to treat acute radiation sickness in the event of a nuclear emergency.

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.